P206 - Which patient population profits best from a high dose, once daily treatment with 3.0g mesalazine for maintaining clinical remission in ulcerative colitis? A subgroup analysis of a double-blind, double-dummy, randomised, controlled, dose-ranging study

✍ Scribed by W. Kruis; L. Jonaitis; L. Kupcinskas; J. Pokrotnieks; G. Acute; T.L. Mikhailova; M. Horynski; M. Batovsky; Y.S. Lozinskii; I. Racz; K. Kull; A. Vcev; M. Faszczyk; R. Greinwald; R. Mueller

• Book ID: 119636321
• Publisher: Oxford University Press
• Year: 2009
• Tongue: English
• Weight: 51 KB
• Volume: 3
• Category: Article
• ISSN: 1873-9946
• DOI: 10.1016/s1873-9946(09)60233-6